SEVERE COUGH A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary f
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
August 29, 2024
End Date
July 11, 2029
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
August 29, 2024
End Date
July 11, 2029